Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.53 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.53 |
| ▸ | HTR1D | P28221 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | HTR1E | P28566 | 1/20 | 0.52 |
| ▸ | HTR7 | P34969 | 1/20 | 0.52 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
| ▸ | HTR6 | P50406 | 1/20 | 0.52 |
| ▸ | MET | P08581 | 9/20 | 0.51 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4713595 | 0.89 | MET (0.50) | MAPK1MAPK3MAP2K1METFLT3 | |
| SCHEMBL5257069 | 0.89 | MAPK1 (0.63) | MAPK1MAPK3MAP2K1HTR1DHTR2A | |
| SCHEMBL2972760 | 0.85 | RBP4 (0.52) | MAPK1MAPK3MAP2K1METFLT3 | |
| SCHEMBL4532938 | 0.80 | MET (0.50) | MAPTHPGDMAPK1MAPK3MAP2K1 | |
| SCHEMBL10818696 | 0.80 | CYP2C19 (0.69) | MAPTHPGDMAPK1HTR1DHTR2A | |
| SCHEMBL4080008 | 0.79 | HMOX1 (0.49) | MAPTHPGDMAPK1MAPK3MAP2K1 | |
| SCHEMBL4093739 | 0.78 | HMOX1 (0.50) | MAPTHPGDMAPK1MAPK3MAP2K1 | |
| SCHEMBL5126874 | 0.78 | HMOX1 (0.52) | MAPK1MAPK3MAP2K1METFLT3 | |
| SCHEMBL17232741 | 0.78 | RBP4 (0.44) | MAPK1MAPK3MAP2K1METFLT3 | |
| SCHEMBL10817743 | 0.77 | MAPK1 (0.80) | MAPTHPGDMAPK1HTR1DHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140179924-A1 | Process for the preparation of cathepsin S inhibitors | JANSSEN PHARMACEUTICA NV (US) | 2014-06-26 | — | — | US | disclosed |
| US-20120142928-A1 | PROCESS FOR THE PREPARATION OF CATHEPSIN S INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179924-A1 | Process for the preparation of cathepsin S inhibitors | CTSS, CTSB, CTSF | MAPT 2838/4885HPGD 2809/4885MAPK1 3307/4885 |
| US-20120142928-A1 | PROCESS FOR THE PREPARATION OF CATHEPSIN S INHIBITORS | CTSS, CTSB, CTSF | MAPT 2838/4885HPGD 2809/4885MAPK1 3307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.